A new daily pill that could transform the way endometriosis is treated has been approved for use on the NHS across England, the medicines watchdog has announced.
About 1,000 women a year living with endometriosis will be able to access relugolix-estradiol-norethisterone. The “first-of-a-kind” treatment, which was initially rejected by the National Institute for Health and Care Excellence (Nice), works by blocking the specific hormones that contribute to endometriosis while providing necessary hormone replacement.
